Eczema (chronic) - alitretinoin: review proposal - August 2012
Review of NICE Technology Appraisal Guidance No.177; Alitretinoin for the treatment of chronic eczema of the hand, refractory to steroids
Proposal to move guidance to the static list
The planned date for review of the above guidance is August 2012.
This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.
No new evidence has emerged since the publication of TA177 and there are no changes in the marketing authorisation or price. There are very few ongoing trials and the results of these are not expected to change the recommendations. Consequently we propose that the original guidance become static.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.
Please see appendix A for a full list of the organisations we have contacted.
This page was last updated: 20 August 2012